Costa RicaTuberculosis profile
Population  2015 4.8 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.049 (0.046–0.052) 1 (0.96–1.1)
Mortality (HIV+TB only) <0.01 (<0.01–0.025) 0.15 (0.01–0.52)
Incidence  (includes HIV+TB) 0.53 (0.41–0.67) 11 (8.5–14)
Incidence (HIV+TB only) 0.041 (0.032–0.052) 0.86 (0.66–1.1)
Incidence (MDR/RR-TB)** 0.012 (<0.01–0.022) 0.25 (0.03–0.46)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.016 (<0.01–0.027) 0.17 (0.093–0.24) 0.18 (0.099–0.27)
Males 0.023 (0.015–0.032) 0.32 (0.24–0.4) 0.35 (0.26–0.43)
Total 0.04 (0.027–0.052) 0.49 (0.42–0.56) 0.53 (0.41–0.67)
TB case notifications, 2015  
Total cases notified 424
Total new and relapse 424
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 98%
          - % pulmonary 86%
          - % bacteriologically confirmed among pulmonary 75%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.11 (0.08–0.15)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 31 7%
          - on antiretroviral therapy 31 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  8
(1–15)
Estimated % of TB cases with MDR/RR-TB 1.9% (0–3.9) 9.1% (1.1–29)  
% notified tested for rifampicin resistance 0% 6% 1
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 89% 455
Previously treated cases, excluding relapse, registered in 2014   0
HIV-positive TB cases, all types, registered in 2014 64% 36
MDR/RR-TB cases started on second-line treatment in 2013   0
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-03-30 Data: www.who.int/tb/data